Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG Intron vs Intron A in newly diagnosed CML
NCT03547154Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 1998
- Primary completion
- Feb 2001
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in chronic myelogenous leukemia (CML) (2 arms), sponsored by Merck & Co. Primary endpoint: Number of Participants With Cytogenetic Responses at 12 months. Started Oct 1998; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT03547154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547154.